Tamara Carvalho

Tamara Carvalho

Auto-generated profile, based on publicly available information

Tamara Carvalho

Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier, CNRS UMR9004 3 , Montpellier

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
BFBarbara Freitas Floriano
Barbara Freitas Floriano
TCTamara Carvalho
Tamara Carvalho
TLTairine Zara Lopes
Tairine Zara Lopes
LTLuandra Aparecida Unten Takahashi
Luandra Aparecida Unten Takahashi
PRPaula Rahal
Paula Rahal
MCMarilia Calmon
Marilia Calmon

14 May 2023 in Viruses
Verified
Journal Article
Open access
PDF file
GAGabriela Miranda Ayusso
Gabriela Miranda Ayusso
MLMaria Letícia Duarte Lima
Maria Letícia Duarte Lima
PSPaulo Ricardo da Silva Sanches
Paulo Ricardo da Silva Sanches
Igor Andrade SantosIgor Andrade Santos
Igor Andrade Santos
DMDaniel Oliveira Silva Martins
Daniel Oliveira Silva Martins
PRPaula Rahal
Paula Rahal
Chikungunya virus (CHIKV) and Zika virus (ZIKV) are important disease-causing agents worldwide. Currently, there are no antiviral drugs or vaccines approved to treat these viruses. However, peptides have shown great potential for new drug development. A recent study described (p-BthTX-I)2K [(KKYRYHLKPF)2K], a peptide derived from the Bothropstoxin-I toxin in the venom of the Bothrops jararacussu snake, showed antiviral activity against SARS-CoV-2. In this study, we assessed the activity of this peptide against CHIKV and ZIKV and its antiviral action in the different stages of the viral replication cycle in vitro. We observed that (p-BthTX-I)2K impaired CHIKV infection by interfering with the early steps of the viral replication cycle, reducing CHIKV entry into BHK-21 cells specifically by reducing both the attachment and internalization steps. (p-BthTX-I)2K also inhibited the ZIKV replicative cycle in Vero cells. The peptide protected the cells against ZIKV infection and decreased the levels of the viral RNA and the NS3 protein of this virus at viral post-entry steps. In conclusion, this study highlights the potential of the (p-BthTX-I)2K peptide to be a novel broad-spectrum antiviral candidate that targets different steps of the replication cycle of both CHIKV and ZIKV.

25 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
RMRenan Moura Martins
Renan Moura Martins
TCTamara Carvalho
Tamara Carvalho
CBCíntia Bittar
Cíntia Bittar
DQDaniela Müller Quevedo
Daniela Müller Quevedo
RMRafael Nava Miceli
Rafael Nava Miceli
MCMarilia Calmon
Marilia Calmon
Wastewater-based epidemiology (WBE) is a tool involving the analysis of wastewater for chemicals and pathogens at the community level. WBE has been shown to be an effective surveillance system for SARS-CoV-2, providing an early-warning-detection system for disease prevalence in the community via the detection of genetic materials in the wastewater. In numerous nation-states, studies have indicated the presence of SARS-CoV-2 in wastewater. Herein, we report the primary time-course monitoring of SARS-CoV-2 RNA in wastewater samples in São José do Rio Preto-SP/Brazil in order to explain the dynamics of the presence of SARS-CoV-2 RNA during one year of the SARS-CoV-2 pandemic and analyze possible relationships with other environmental parameters. We performed RNA quantification of SARS-CoV-2 by RT-qPCR using N1 and N2 targets. The proportion of positive samples for every target resulted in 100% and 96.6% for N1 and N2, respectively. A mean lag of -5 days is observed between the wastewater signal and the new SARS-CoV-2-positive cases reported. A correlation was found between the air and wastewater temperatures and therefore between the SARS-CoV-2 viral titers for N1 and N2 targets. We also observed a correlation between SARS-CoV-2 viral titers and media wastewater flow for the N1 target. In addition, we observed higher viral genome copies within the wastewater samples collected on non-rainy days for the N1 target. Thus, we propose that, based on our results, monitoring raw wastewater may be a broadly applicable strategy that might contribute to resolving the pressing problem of insufficient diagnostic testing; it may represent an inexpensive and early-warning method for future COVID-19 outbreaks, mainly in lower- and middle-income countries.

11 August 2025 in Nature Communications
Verified
Journal Article
Open access
JAJohn Jairo Aguilera-Correa
John Jairo Aguilera-Correa
YTYara Tasrini
Yara Tasrini
MGMiguel Gisbert-Garzarán
Miguel Gisbert-Garzarán
ABAude Boulay
Aude Boulay
TCTamara Carvalho
Tamara Carvalho
LKLaurent Kremer
Laurent Kremer
Treatments of Mycobacterium marinum, a common non-tuberculous mycobacterium associated with cutaneous infections are very challenging, emphasizing the development of new therapeutic approaches. Here we report the functionalization of mesoporous silica nanoparticles (MSN) with a series of triphenylphosphonium (TPP) substituents, which endowed them with affinity towards the surface of M. marinum in vitro, as well as within infected THP-1 cells. The presence of these nanoparticles at the bacterial surface prevents their uptake by human macrophages and dendritic cells. When loaded with doxycycline, the nanosystem exerts a potent anti-bacterial effect in planktonic cultures, biofilms, and in M. marinum-infected macrophages. Strikingly, in the M. marinum/zebrafish infection model, the doxycycline-loaded nanoparticles are associated with a pronounced decrease in the bacterial burden and a high embryo survival rate. These results disclose the proposed MSN nanosystems as a promising alternative for the treatment of M. marinum infection and, presumably, against a broader range of mycobacterial infections.

1 March 2023 in Viruses
Verified
Journal Article
Open access
PDF file
VCVivaldo Gomes da Costa
Vivaldo Gomes da Costa
AGAna Julia Gomes
Ana Julia Gomes
CBCíntia Bittar
Cíntia Bittar
DGDayla Bott Geraldini
Dayla Bott Geraldini
Pâmela Previdelli Da ConceiçãoPâmela Previdelli Da Conceição
Pâmela Previdelli Da Conceição
PRPaula Rahal
Paula Rahal
Non-SARS-CoV-2 respiratory viral infections, such as influenza virus (FluV) and human respiratory syncytial virus (RSV), have contributed considerably to the burden of infectious diseases in the non-COVID-19 era. While the rates of co-infection in SARS-CoV-2-positive group (SCPG) patients have been determined, the burden of other respiratory viruses in the SARS-CoV-2-negative group (SCNG) remains unclear. Here, we conducted a cross-sectional study (São José do Rio Preto county, Brazil), and we collected our data using a meta-analysis to evaluate the pooled prevalence of FluV and RSV among SCNG patients. Out of the 901 patients suspected of COVID-19, our molecular results showed positivity of FluV and RSV in the SCNG was 2% (15/733) and 0.27% (2/733), respectively. Co-infection with SARS-CoV-2 and FluV, or RSV, was identified in 1.7% of the patients (3/168). Following our meta-analysis, 28 studies were selected (n = 114,318 suspected COVID-19 patients), with a pooled prevalence of 4% (95% CI: 3–6) for FluV and 2% (95% CI: 1–3) for RSV among SCNG patients were observed. Interestingly, FluV positivity in the SCNG was four times higher (OR = 4, 95% CI: 3.6–5.4, p < 0.01) than in the SCPG. Similarly, RSV positivity was significantly associated with SCNG patients (OR = 2.9, 95% CI: 2–4, p < 0.01). For subgroup analysis, cold-like symptoms, including fever, cough, sore throat, headache, myalgia, diarrhea, and nausea/vomiting, were positively associated (p < 0.05) with the SCPG. In conclusion, these results show that the pooled prevalence of FluV and RSV were significantly higher in the SCNG than in the SCPG during the early phase of the COVID-19 pandemic.

30 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GAGabriela Miranda Ayusso
Gabriela Miranda Ayusso
PSPaulo Ricardo da Silva Sanches
Paulo Ricardo da Silva Sanches
TCTamara Carvalho
Tamara Carvalho
Igor Andrade SantosIgor Andrade Santos
Igor Andrade Santos
DMDaniel Oliveira Silva Martins
Daniel Oliveira Silva Martins
MCMarilia Calmon
Marilia Calmon
Chikungunya virus (CHIKV) belongs to the Alphavirus genus and is responsible for significant outbreaks worldwide. Currently, there is no approved antiviral therapy against CHIKV. Bioactive peptides have great potential for new drug development. Here, we evaluated the antiviral activity of the synthetic peptide GA-Hecate and its analogs PSSct1905 and PSSct1910 against CHIKV infection. Initial screening showed that all three peptides inhibited the CHIKV replication cycle in baby hamster kidney fibroblast cells (BHK-21) and human hepatocarcinoma epithelial cells (Huh-7). GA-Hecate and its analog PSSct1905 were the most active, demonstrating suppression of viral infection by more than 91%. The analog PSSct1905 exhibited a protective effect in cells against CHIKV infection. We also observed that the analogs PSSct1905 and PSSct1910 affected CHIKV entry into both cell lines, inhibiting viral attachment and internalization. Finally, all tested compounds presented antiviral activity on the post-entry steps of CHIKV infection in all cells evaluated. In conclusion, this study highlights the potential of the peptide GA-Hecate and its analogs as novel anti-CHIKV compounds targeting different stages of the viral replication cycle, warranting the development of GA-Hecate-based compounds with broad antiviral activity.